Ling Xue Selected Research

Met Transfer RNA

1/2018	A hypertension-associated mitochondrial DNA mutation introduces an m1G37 modification into tRNAMet, altering its structure and function.
2/2014	[The mitochondrial tRNAMet/tRNAGlnA4401G and tRNACysG5821A mutations may be associated with hypertension in two Han Chinese families].
11/2011	The tRNAMet 4435A>G mutation in the mitochondrial haplogroup G2a1 is responsible for maternally inherited hypertension in a Chinese pedigree.
9/2011	[Mutations in mitochondrial DNA associated with hypertension].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ling Xue Research Topics

Disease

23	Neoplasms (Cancer) 01/2022 - 10/2004
13	Hypertension (High Blood Pressure) 07/2021 - 09/2011
12	Infections 01/2022 - 01/2014
10	Aortic Dissection 01/2022 - 05/2012
9	Myocardial Infarction 01/2022 - 07/2007
9	ST Elevation Myocardial Infarction 01/2022 - 01/2020
7	Stomach Neoplasms (Stomach Cancer) 01/2018 - 07/2010
6	Acute Coronary Syndrome 01/2022 - 06/2011
6	Mitochondrial Diseases (Mitochondrial Disease) 01/2021 - 08/2012
6	Breast Neoplasms (Breast Cancer) 02/2019 - 03/2005
5	Acute Kidney Injury (Acute Renal Failure) 01/2022 - 01/2017
5	Essential Hypertension 01/2015 - 09/2011
4	Adenocarcinoma 01/2022 - 05/2012
4	Inflammation (Inflammations) 01/2021 - 06/2002
4	Deafness (Deaf Mutism) 01/2019 - 05/2010
4	Premenstrual Syndrome (Premenstrual Tension) 06/2017 - 12/2011
4	Hearing Loss (Hearing Impairment) 02/2017 - 05/2010
4	Diabetic Nephropathies (Diabetic Nephropathy) 01/2016 - 07/2011
4	Hepatocellular Carcinoma (Hepatoma) 03/2014 - 02/2007
3	Stroke (Strokes) 01/2022 - 01/2019
3	Spinal Cord Ischemia 01/2022 - 11/2013
3	Endoleak 01/2022 - 01/2019
3	Wounds and Injuries (Trauma) 05/2021 - 12/2012
3	Carcinoma (Carcinomatosis) 01/2015 - 07/2007
3	Myocardial Ischemia (Ischemic Heart Diseases) 11/2014 - 03/2008
3	Reperfusion Injury 11/2014 - 11/2005
2	Thrombocytopenia (Thrombopenia) 01/2022 - 01/2021
2	Ischemia 01/2022 - 03/2008
2	Fibrosis (Cirrhosis) 01/2022 - 07/2018
2	Hemorrhage 12/2021 - 01/2021
2	Pneumonia (Pneumonitis) 07/2020 - 01/2020
2	Aortic Rupture 01/2019 - 01/2013
2	Hypotension (Low Blood Pressure) 11/2018 - 07/2007
2	Crohn Disease (Crohn's Disease) 06/2018 - 02/2015
2	Neoplasm Metastasis (Metastasis) 01/2018 - 01/2014
2	Lymphatic Metastasis 01/2018 - 07/2010
2	Neuroendocrine Tumors (Neuroendocrine Tumor) 09/2017 - 03/2017
2	Nonsyndromic Deafness 01/2017 - 06/2010
2	Coronary Disease (Coronary Heart Disease) 01/2014 - 10/2013
2	Aortic Diseases 01/2014 - 05/2012
2	Renal Insufficiency (Renal Failure) 10/2012 - 07/2010
2	Atherosclerosis 06/2011 - 09/2009
2	Cardiac Arrhythmias (Arrythmia) 03/2008 - 07/2007
2	Osteosarcoma (Osteogenic Sarcoma) 01/2008 - 09/2007

Drug/Important Bio-Agent (IBA)

18	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2008
11	Mitochondrial DNA (mtDNA)IBA 01/2021 - 05/2010
10	Transfer RNA (tRNA)IBA 01/2019 - 08/2012
8	omega-Chloroacetophenone (Mace)IBA 01/2022 - 10/2007
8	Messenger RNA (mRNA)IBA 01/2021 - 01/2008
6	DNA (Deoxyribonucleic Acid)IBA 01/2017 - 05/2011
5	Biomarkers (Surrogate Marker)IBA 12/2021 - 05/2012
4	Pharmaceutical PreparationsIBA 01/2021 - 06/2002
4	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 08/2020 - 03/2008
4	Biological ProductsIBA 07/2020 - 02/2007
4	CholesterolIBA 06/2020 - 03/2008
4	Met Transfer RNAIBA 01/2018 - 09/2011
4	anisodamineIBA 10/2012 - 07/2007
4	CytokinesIBA 08/2012 - 05/2008
3	RNA (Ribonucleic Acid)IBA 01/2022 - 05/2012
3	Clopidogrel (Plavix)FDA Link 01/2021 - 10/2014
3	MicroRNAs (MicroRNA)IBA 07/2020 - 05/2012
3	Ser Transfer RNAIBA 01/2019 - 05/2010
3	Capsules (Microcapsules)IBA 01/2018 - 12/2014
3	NucleotidesIBA 01/2018 - 06/2010
3	12S ribosomal RNAIBA 01/2017 - 06/2010
3	3,3'-diindolylmethane (diindolylmethane)IBA 05/2008 - 02/2006
3	Interferon-gamma (Interferon, gamma)IBA 05/2008 - 03/2005
2	Long Noncoding RNAIBA 01/2022 - 01/2021
2	Phosphotransferases (Kinase)IBA 08/2021 - 01/2016
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 04/2015
2	TicagrelorIBA 01/2021 - 06/2018
2	Atorvastatin (Lipitor)FDA Link 08/2020 - 06/2011
2	Triglycerides (Triacylglycerol)IBA 06/2020 - 11/2013
2	AntigensIBA 01/2020 - 05/2011
2	VaccinesIBA 01/2020 - 12/2018
2	AntibodiesIBA 01/2020 - 02/2007
2	Peptides (Polypeptides)IBA 01/2020 - 02/2017
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2018 - 08/2012
2	Peptide Hydrolases (Proteases)FDA Link 01/2018 - 01/2014
2	Therapeutic UsesIBA 06/2017 - 12/2014
2	Adenosine Triphosphate (ATP)IBA 02/2017 - 05/2006
2	AminoglycosidesIBA 01/2017 - 06/2010
2	Ala Transfer RNAIBA 01/2016 - 05/2010
2	Streptozocin (Streptozotocin)FDA Link 01/2016 - 07/2011
2	HLA-B Antigens (HLA-B)IBA 11/2015 - 09/2011
2	Beclin-1IBA 01/2015 - 07/2011
2	Simvastatin (Zocor)FDA LinkGeneric 09/2009 - 03/2008
2	indole-3-carbinolIBA 05/2008 - 04/2005
2	indoleIBA 05/2008 - 02/2006
2	NK Cell Lectin-Like Receptor Subfamily KIBA 01/2008 - 09/2007
2	micaIBA 01/2008 - 09/2007
2	Estrogens (Estrogen)FDA Link 02/2006 - 04/2005

Therapy/Procedure

15	Percutaneous Coronary Intervention 01/2022 - 07/2007
11	Endovascular Aneurysm Repair 01/2022 - 01/2013
7	Therapeutics 08/2021 - 09/2009
6	Stents 07/2021 - 01/2013
3	Length of Stay 01/2020 - 07/2010
2	Punctures 01/2022 - 10/2019
2	Immunotherapy 01/2021 - 09/2007
2	Aftercare (After-Treatment) 01/2018 - 03/2014